01:25 , May 10, 2016 |  BC Extra  |  Company News

Medicines Co. selling some CV assets to Chiesi

The Medicines Co. (NASDAQ:MDCO) is selling its non-core cardiovascular assets to Chiesi Farmaceutici S.p.A. (Parma, Italy). The deal includes Cleviprex clevidipine , Kengreal cangrelor and the company's rights to ready to use argatroban . It...
08:00 , Nov 11, 2013 |  BioCentury  |  Finance

OrbiMed's high five

At a time when many life science VCs are raising smaller funds, OrbiMed Advisors closed what might be the largest pure venture fund in over a decade, raising more than $735 million from LPs who...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

IV nicardipine-containing medicines regulatory update

EMA's CHMP determined that IV nicardipine-containing medicines should only be used to treat acute life-threatening hypertension and post-operative hypertension. The committee also recommended that nicardipine be given only by continuous infusion into a vein by...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Cornerstone Therapeutics, Exela PharmSci Inc. cardiovascular news

Cornerstone filed a suit in the U.S. District Court for the District of Delaware alleging that an sNDA submitted by Exela for an injectable formulation of 0.1 and 0.2 mg/mL nicardipine in 0.9% sodium chloride...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Cornerstone Therapeutics, Exela PharmSci Inc. cardiovascular news

Cornerstone received a Paragraph IV notification letter from Exela PharmaSci's Exela Pharma Sciences LLC (Lenoir, N.C.) subsidiary indicating that it submitted an sNDA to FDA for an injectable formulation of 0.1 and 0.2 mg/mL nicardipine...
07:00 , Jun 17, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) was up $0.56 (12%) to $5.05 last week after the U.K.'s NICE issued draft guidance recommending Iluvien fluocinolone acetonide intravitreal implant for chronic diabetic macular edema (DME) patients considered...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Clinical News

Cleviprex clevidipine: Phase III data

Top-line data from the open-label, international Phase III PRONTO trial in 104 emergency department hypertensive AHF patients who exhibited pulmonary congestion showed that IV clevidipine met the composite primary endpoint of median time and percent...
07:00 , May 21, 2012 |  BC Week In Review  |  Company News

Cornerstone Therapeutics, EKR deal

Cornerstone will acquire EKR for $125 million in cash plus up to $25 million in milestones over the next three years. Cornerstone said the deal expands its product offerings and commercial infrastructure in the hospital...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Clinical News

Cardene I: Phase IV data

The open-label, U.S. Phase IV CLUE trial in 226 patients admitted to the emergency room with 2 SBP readings of >180 mmHg measured >=10 minutes apart showed that a significantly greater proportion of patients receiving...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Clinical News

Cardene I: Interim Phase IV data

Interim data from an open-label, U.S. Phase IV trial in 47 patients showed that a significantly greater proportion of patients receiving Cardene I.V. achieved their target blood pressure by 24 hours vs. IV labetalol (100%...